Samso has been following the Echo IQ since September 2025. The research that went into preparing for the first Coffee with Samso with Dustin Haines was the eye opener for myself. It became very clear that this was a business that just needed validation and the first was the FDA submission which I now understand is not something that is caually done. The proecess and the acceptance of the request for approval in itself was a strenous process and is almost a tick of approval

This Coffee with Samso conversation with Dustin Haines from Echo IQ Limited (ASX: EIQ) reinforces a clear investment narrative: this is not just an AI story, but a data-driven healthcare business building a scalable diagnostic platform anchored in real clinical need.

Echo IQ Ltd (ASX: EIQ) has expanded its agreement with Mayo Clinic to enable the potential resale and distribution of its heart failure decision support solution, EchoSolv HF, following FDA clearance. I have liked the Echo IQ story from the first time I was introduced to it. The business is operating in a space where clinical validation, regulatory approval, and commercial deployment must align before revenue can be realised.

Echo IQ Limited (ASX: EIQ) has delivered a concise update showing rising clinical usage for EchoSolv™ AS, clear progress on EchoSolv™ HF’s FDA pathway, and expanding commercial channels in the US and Europe. The near-term catalysts are anchored in actual hospital integrations, validation work nearing completion, and newly appointed US key opinion leaders guiding adoption.

In the crowded corridors of medtech innovation, it's easy to get swept up in buzzwords—AI-powered, minimally invasive, precision diagnostics. But every now and then, a company emerges with more than just jargon—it comes armed with transformative tech, a clear path to market, and the traction to back it up.